These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1265 related items for PubMed ID: 18021866

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Zoster vaccine protects against shingles.
    BMJ; 2013 Apr 17; 346():f2389. PubMed ID: 23596220
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.
    Doan HQ, Ung B, Ramirez-Fort MK, Khan F, Tyring SK.
    Expert Opin Biol Ther; 2013 Oct 17; 13(10):1467-77. PubMed ID: 23984934
    [Abstract] [Full Text] [Related]

  • 25. Vaccine against herpes zoster halves incidence in older people, finds study.
    Ramsey S.
    BMJ; 2013 Apr 12; 346():f2349. PubMed ID: 23585074
    [No Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J, Robertus K.
    Ann Intern Med; 2006 Sep 05; 145(5):317-25. PubMed ID: 16954357
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Varicella zoster vaccines.
    Creed R, Satyaprakash A, Ravanfar P.
    Dermatol Ther; 2009 Sep 05; 22(2):143-9. PubMed ID: 19335725
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.
    Brisson M, Pellissier JM, Levin MJ.
    Clin Infect Dis; 2007 Dec 01; 45(11):1527-9. PubMed ID: 17990240
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Herpes zoster and post-herpetic neuralgia in older adults].
    Lang PO, Zarate-Lagunes M, Pautex S.
    Rev Med Suisse; 2008 Nov 05; 4(178):2398-402, 2404. PubMed ID: 19051627
    [Abstract] [Full Text] [Related]

  • 35. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
    Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW, Protocol 009 Study Group.
    Vaccine; 2007 Feb 26; 25(10):1877-83. PubMed ID: 17227688
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB, Virapongse A, Smith KJ.
    Clin Infect Dis; 2007 May 15; 44(10):1280-8. PubMed ID: 17443464
    [Abstract] [Full Text] [Related]

  • 39. Prevention of shingles by varicella zoster virus vaccination.
    Holodniy M.
    Expert Rev Vaccines; 2006 Aug 15; 5(4):431-43. PubMed ID: 16989624
    [Abstract] [Full Text] [Related]

  • 40. A novel vaccine (Zostavax) to prevent herpes zoster.
    Holcomb K, Weinberg JM.
    G Ital Dermatol Venereol; 2008 Apr 15; 143(2):119-23. PubMed ID: 18833038
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 64.